Format
Sort by
Items per page

Send to

Choose Destination

Best matches for RIVASTIGMINE/TU:

Search results

Items: 1 to 20 of 93

1.

Cholinesterase inhibitors for the treatment of delirium in non-ICU settings.

Yu A, Wu S, Zhang Z, Dening T, Zhao S, Pinner G, Xia J, Yang D.

Cochrane Database Syst Rev. 2018 Jun 28;6:CD012494. doi: 10.1002/14651858.CD012494.pub2. Review.

PMID:
29952000
2.

A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.

McDonald J, Pourcher E, Nadeau A, Corbeil P.

Clin Neuropharmacol. 2018 May/Jun;41(3):87-93. doi: 10.1097/WNF.0000000000000275.

PMID:
29537978
3.

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.

Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL.

JAMA. 2018 Jan 9;319(2):130-142. doi: 10.1001/jama.2017.20373.

4.

A chiral enantioseparation generic strategy for anti-Alzheimer and antifungal drugs by short end injection capillary electrophoresis using an experimental design approach.

Abdel-Megied AM, Hanafi RS, Aboul-Enein HY.

Chirality. 2018 Feb;30(2):165-176. doi: 10.1002/chir.22777. Epub 2017 Nov 20.

PMID:
29154400
5.

Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics.

Wavikar P, Pai R, Vavia P.

J Pharm Sci. 2017 Dec;106(12):3613-3622. doi: 10.1016/j.xphs.2017.08.024. Epub 2017 Sep 15.

PMID:
28923321
6.

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.

Muñoz-Moreno JA, Prats A, Moltó J, Garolera M, Pérez-Álvarez N, Díez-Quevedo C, Miranda C, Fumaz CR, Ferrer MJ, Clotet B; TRIANT-TE Study Group.

PLoS One. 2017 Aug 30;12(8):e0182547. doi: 10.1371/journal.pone.0182547. eCollection 2017.

7.

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.

Park KW, Kim EJ, Han HJ, Shim YS, Kwon JC, Ku BD, Park KH, Yi HA, Kim KK, Yang DW, Lee HW, Kang H, Kwon OD, Kim S, Lee JH, Chung EJ, Park SW, Park MY, Yoon B, Kim BC, Seo SW, Choi SH.

PLoS One. 2017 Aug 7;12(8):e0182123. doi: 10.1371/journal.pone.0182123. eCollection 2017.

8.

Utilization of Western medicine and traditional Chinese medicine among patients with Alzheimer's disease in Taiwan: a nationwide population-based study.

Lai CY, Wu MY, Chiang JH, Sun MF, Chen YH, Chang CT, Lin JG, Yen HR.

Eur J Neurol. 2017 Sep;24(9):1166-1172. doi: 10.1111/ene.13361. Epub 2017 Jul 26.

PMID:
28744942
9.

Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.

Mohammad D, Chan P, Bradley J, Lanctôt K, Herrmann N.

Expert Opin Drug Saf. 2017 Sep;16(9):1009-1019. doi: 10.1080/14740338.2017.1351540. Epub 2017 Jul 12. Review.

PMID:
28678552
10.

Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers.

Abhyankar D, Shedage A, Gole M, Raut P.

Am J Alzheimers Dis Other Demen. 2017 Sep;32(6):360-366. doi: 10.1177/1533317517712890. Epub 2017 Jul 3.

PMID:
28670911
11.

Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.

Servello A, Ettorre E, Cacciafesta M.

Panminerva Med. 2017 Sep;59(3):275-277. doi: 10.23736/S0031-0808.17.03274-8. No abstract available.

PMID:
28665099
12.

Treating 'Devil׳s Breath׳ intoxication: Use of rivastigmine in six patients with toxic psychoses due to non pharmaceutical scopolamine.

Sandia S I, Ramírez V J, Piñero A J, Baptista T T.

Eur Neuropsychopharmacol. 2017 Aug;27(8):833-834. doi: 10.1016/j.euroneuro.2017.05.006. Epub 2017 Jun 7. No abstract available.

PMID:
28601550
13.

Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan.

Chen TH, Chou MC, Lai CL, Wu SJ, Hsu CL, Yang YH.

Kaohsiung J Med Sci. 2017 Jun;33(6):277-283. doi: 10.1016/j.kjms.2017.04.006. Epub 2017 May 22.

14.

Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.

Suzuki Y, Kamijo Y, Yoshizawa T, Fujita Y, Usui K, Kishino T.

Clin Toxicol (Phila). 2017 Nov;55(9):1008-1010. doi: 10.1080/15563650.2017.1329536. Epub 2017 Jun 8.

PMID:
28594244
15.

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.

Kandiah N, Pai MC, Senanarong V, Looi I, Ampil E, Park KW, Karanam AK, Christopher S.

Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. eCollection 2017. Review.

16.

Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease.

Hsu CW, Lee Y, Lee CY, Lin PY.

Clin Neuropharmacol. 2017 May/Jun;40(3):147-148. doi: 10.1097/WNF.0000000000000215.

PMID:
28452906
17.

Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders.

Schultz BR, Takeshita J, Goebert D, Takeshita S, Lu BY, Guilloux A, Higa J.

Psychogeriatrics. 2017 Nov;17(6):423-429. doi: 10.1111/psyg.12267. Epub 2017 Apr 7.

PMID:
28387023
18.

Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.

Campbell NL, Perkins AJ, Gao S, Skaar TC, Li L, Hendrie HC, Fowler N, Callahan CM, Boustani MA.

J Am Geriatr Soc. 2017 Jul;65(7):1497-1504. doi: 10.1111/jgs.14827. Epub 2017 Mar 14.

PMID:
28295141
19.

Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial Apparatuses: USP 5 and USP 6.

Simon A, Amaro MI, Healy AM, Cabral LM, de Sousa VP.

AAPS PharmSciTech. 2017 Oct;18(7):2561-2569. doi: 10.1208/s12249-017-0738-9. Epub 2017 Feb 21.

PMID:
28224389
20.

Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.

Fisher A, Carney G, Bassett K, Dormuth CR.

Drugs Aging. 2017 Mar;34(3):221-231. doi: 10.1007/s40266-017-0438-x.

PMID:
28138912

Supplemental Content

Loading ...
Support Center